Wednesday, 19 August 2020

Ozone Therapy in the Treatment of Symptoms Associated to Trigeminal Neuralgia by Roxana Mirica in Open access Journal of Biogenerc Science and Research

 Ozone Therapy in the Treatment of Symptoms Associated to Trigeminal Neuralgia by Roxana Mirica in Open access Journal of Biogenerc Science and Research

 

 

Abstract
Background

Trigeminal neuralgia: Manifests as an extremely intense neuropathic pain that affects the patient’s life in all its aspects. The classical -according to the guides -treatment with Carbamazepine has various adverse reactions. Patients have a low compliance too, and stop the treatment. Analgesia through acupuncture was thoroughly studied in the meta-analysis conducted by Vickers et al. on 20,827 patients in 2017. We propose ozone therapy on trigger points as treatment, the antialgic effect of acupuncture being doubled with the trophic effect of the oxygen. Treatment, the antialgic effect of acupuncture being doubled with the trophic effect of the oxygen.Measures: A 54 years old patient with hemicrania and hypersensitivity on the right side of the face, who spoke with his mouth almost closed, after 12 sessions of ozone therapy, felt no pain, the symptoms were significantly improved.


Intervention: For an objective assessment of the treatment effect, we used VAS (Visual Analog Scale). Patients’ compliance to pain assessment is low, but the person feeling it is the only one who can accurately assess its intensity. Outcomes: Ozone is used in chronic diseases, in treating pain and for rejuvenation purposes, by injections, insufflations, autohemotransfusion and locally applied. Conclusion: Ozone therapy could be a first line treatment in trigeminal neuralgia, because it has no adverse effects, relief pain and increase quality of life of the patients.

Keywords: Pain; Trigeminal neuralgia; Ozone; Trigger points; Acupuncture; VAS scale

Introduction
Trigeminal neuralgia includes a complex of painful, intensely explosive (electric shock-like) manifestation in the oral and maxillofacialarea, sometimes accompanied by sweating or local hypersensitivity. The patient’s quality of life decreases dramatically as the pain is often debilitating and becomes chronic if left untreated. The “trigeminal” pain is a complex response from the body to certain stimuli, sometimes generated by inflammation along the trigeminal nerve route (fifth cranial nerve)or its branches (ophthalmic, maxillary, mandibular) [1] (Figure 1). This is a neuropathic, intense, explosive, repetitive and severe pain that lasts a few minutes [2], with a re-entry mechanism that causes enhancement of the sensorial perception. It is virtually a vicious circle.

In 2017, Kesand Matovina classified trigeminal neuralgia in 3 categories:
Classical (continued paroxistic pain). Secondary (associated with other neurological diseases or cerebral space replacement formations) Idiopathic [2]. Secondary trigeminal neuralgia with an identifiable cause is rare. The primary idiopathic form is the most common. The trigeminal neuralgia prevalence in the global population is 4/100,000 inhabitants, higher among women aged >50[1/2].The treatment for trigeminal neuralgia includes analgesic, anti-inflammatory, anticonvulsant medication (Carbamazepine, the treatment of choice according to the European guidelines), antidepressant medications, surgical treatment for nerve branch isolation or even sectioning thereof. Based on our real-world setting observations, acupuncture treatmentsor ozone therapiesare highly likely to cure the patient, especially in idiopathic, recent onset cases (less than 6 months).
 

To know more about this article click on 
For Online Submissions Click on https://biogenericpublishers.com/submit-manuscript/

 

Wednesday, 5 August 2020

The Experience with the Use of Nandrolone Decanoate and Pyritinol in Children with Cerebral Palsy by Aamir Jalal Al-Mosawi in Biogeneric Science and Research


Abstract

        Background: Cerebral palsy is a heterogeneous disorder resulting from a non-progressive damage to the developing brain that cause mostly a variable degree of chronic motor disability and developmental abnormalities during early childhood including delayed speech and motor development. Because of the heterogeneous nature of the condition and variable severity and presentations, patients are generally treated with an individualized treatment plans that provides a combination of interventions including treatment of spasticity with muscle relaxants and physical therapy. Patients with severe condition can have significant disability, while patients with less severe disorder experience delay in motor developments and learning difficulties. The aim of this paper is to describe retrospectively our experience with use of nandrolone decanoate (ND) and pyritinol in children with a less severe form of cerebral palsy with aim of improving motor functions and learning abilities.

        Patients and Methods: Five patients (3 males and 2 girls) with cerebral palsy presenting mainly with spasticity, hyperreflexia and delayed speech and motor development. The patients were treated with intermittent low dose intra-muscular (i.m) injections of ND (12.5 mg for children under 2 years, 25 mg for the older child) with the aim of improving their delayed motor development. Pyritinol was used in the one patient in addition to ND with aim of improving his learning abilities. Estimation of the bone age was made using radiographs of the left wrist before the injection and 2 weeks after each injection. The patient was monitored weekly for the development of hypertension and sign of virilization. All the patients had normal or delayed bone age before treatment.

        Results: The use of nandrolone decanoate intramuscular injections and pyritinol was associated with dramatic effect on the motor development and learning abilities respectively without the occurrence of any adverse effects. Mild advancement of bone age was noticed only in one patient.

        Conclusion: nandrolone decanoate and pyritinol can be useful in the management of cerebral palsy.

Keywords: Cerebral palsy, Development, Nandrolone, Pyritinol.

Introduction

Cerebral palsy is a heterogeneous disorder resulting from a non-progressive damage to the developing brain that cause mostly a variable degree of chronic motor disability and developmental abnormalities during early childhood including delayed speech and motor development. Because of the heterogeneous nature of the condition and variable severity and presentations, patients are generally treated with an individualized treatment plans that provides a combination of interventions including treatment of spasticity with muscle relaxants and physical therapy. Patients with severe condition can have significant disability, while patients with less severe disorder experience delay in motor developments and learning difficulties [1-3]. The aim of this paper is to describe retrospectively our experience with use of nandrolone decanoate (ND) and pyritinol in children with a less severe form of cerebral palsy with aim of improving motor functions and learning abilities.


To know more about this article click on